Good morning, everyone, and how are you today? We are doing swell, thank you, helped along by a bright, shiny sun enveloping the chilly Pharmalot campus, where the short person has left for the local schoolhouse and the official mascots are lounging about. We, however, are as busy as ever, quaffing cups of stimulation and foraging for tidbits. Speaking of which, here a few. Hope your day goes well and you conquer the world …

Multiple pharmaceutical executives are expected to add their names to a letter expressing concern about the effects of immigration restrictions on the industry, BioCentury reports. More than 160 biotech industry executives have already signed the letter, which was published earlier this week by Nature Biotechnology and included broader criticism of the implications of the new restrictions for the US.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy